Chk1 inhibitors have previously been tested in a range of cancer cell lines and shown to varying extents to improve cellular sensitivity to different DNA damaging chemotherapeutic agents in some cases boosting sensitivity to agents such as hydroxyurea or gemcitabine but not to 5-FU in CRC [22-24]. This evidence concerns the gene CHEK1 and colorectal carcinoma.